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syndromes: the AMIS model
Abstract
Background: Early risk stratification is important in the management of patients with acute coronary
syndromes (ACS). 
Objective: To develop a rapidly available risk stratification tool for use in all ACS. 
Design and methods: Application of modern data mining and machine learning algorithms to a
derivation cohort of 7520 ACS patients included in the AMIS (Acute Myocardial Infarction in
Switzerland)-Plus registry between 2001 and 2005; prospective model testing in two validation cohorts. 
Results: The most accurate prediction of in-hospital mortality was achieved with the “Averaged
One-Dependence Estimators” (AODE) algorithm, with input of 7 variables  available at first patient
contact: Age, Killip class, systolic blood pressure, heart rate, pre-hospital cardio-pulmonary
resuscitation, history of heart failure, history of cerebrovascular disease. The c-statistic for the derivation
cohort (0.875) was essentially maintained in  important subgroups, and calibration over five risk
categories, ranging from <1% to >30% predicted mortality, was accurate. Results were validated
prospectively against an independent AMIS-Plus cohort (n=2854, c-statistic 0.868) and the
Krakow-Region ACS Registry (n=2635, c-statistic 0.842). The AMIS model significantly outperformed
established “point-of-care” risk prediction tools in both validation cohorts. In comparison to a logistic 
regression-based model, the AODE-based model proved to be more robust when tested on the Krakow
validation cohort (c-statistic 0.842 vs. 0.746). Accuracy of the AMIS model  prediction was maintained
at 12-months follow-up in an independent cohort (n=1972, c-statistic 0.877). 
Conclusions: The AMIS model is a reproducibly accurate point-of-care risk stratification tool for the
complete range of ACS, based on variables available at first patient contact. 
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ABSTRACT 
Background: Early risk stratification is important in the management of patients with acute 
coronary syndromes (ACS).  
Objective: To develop a rapidly available risk stratification tool for use in all ACS. 
Design and methods: Application of modern data mining and machine learning algorithms to 
a derivation cohort of 7520 ACS patients included in the AMIS (Acute Myocardial Infarction 
in Switzerland)-Plus registry between 2001 and 2005; prospective model testing in two 
validation cohorts. 
Results: The most accurate prediction of in-hospital mortality was achieved with the 
“Averaged One-Dependence Estimators” (AODE) algorithm, with input of 7 variables 
available at first patient contact: Age, Killip class, systolic blood pressure, heart rate, pre-
hospital cardio-pulmonary resuscitation, history of heart failure, history of cerebrovascular 
disease. The c-statistic for the derivation cohort (0.875) was essentially maintained in 
important subgroups, and calibration over five risk categories, ranging from <1% to >30% 
predicted mortality, was accurate. Results were validated prospectively against an 
independent AMIS-Plus cohort (n=2854, c-statistic 0.868) and the Krakow-Region ACS 
Registry (n=2635, c-statistic 0.842). The AMIS model significantly outperformed established 
“point-of-care” risk prediction tools in both validation cohorts. In comparison to a logistic 
regression-based model, the AODE-based model proved to be more robust when tested on the 
Krakow validation cohort (c-statistic 0.842 vs. 0.746). Accuracy of the AMIS model 
prediction was maintained at 12-months follow-up in an independent cohort (n=1972, c-
statistic 0.877). 
Conclusions: The AMIS model is a reproducibly accurate point-of-care risk stratification tool 
for the complete range of ACS, based on variables available at first patient contact. 
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INTRODUCTION 
The risk of short-term death for patients suffering from acute coronary syndromes (ACS) is 
widely heterogeneous. Reliable risk stratification remains an essential part of their care,[1] 
especially with regard to the time point of revascularisation, use of antithrombotic therapies, 
and to the length and level of their specialized care and monitoring. For this goal, a number of 
risk prediction models have been developed,[2-13] and among these, models developed from 
randomised controlled trials and later validated in large registries have reached broad 
acceptance.[11, 14, 15] 
Nonetheless, questions have arisen concerning the performance of these scores in patients 
treated according to current standards. First, some of these scores were developed in an era 
prior to the introduction of potent antiplatelet / antithrombotic agents and the establishment of 
percutaneous coronary intervention (PCI) as the treatment of choice for most patients with 
ACS, and the impact of these changes in treatment strategy on the accuracy of risk scores 
remains unclear. Second, many high risk patients were excluded from the trials from which 
the scores were developed, including patients with cardiogenic shock or pre-hospital 
resuscitation, patients with a history of cerebrovascular disease und coagulation disorders, and 
patients with ST elevation myocardial infarction (STEMI) presenting too late for fibrinolytic 
treatment.[6, 7, 9, 11] Third, these scores were all applicable selectively to patients with either 
STEMI or non ST elevation ACS (non-STE-ACS).[6-9, 11-13]  
Recently, the Global Registry of Acute Coronary Events (GRACE) investigators reported a 
prediction score valid over the complete spectrum of ACS.[16] This score has undergone 
extensive validation and has reached broad acceptance. Treatment guidelines of the European 
Society of Cardiology for non-STE-ACS recommend use of the GRACE score as the 
preferred risk stratification tool in routine practice.[1] However, in contrast to the TIMI risk 
scores for STEMI,[7, 9] but in line with the TIMI risk score for Non-STE-ACS,[8] this score 
requires the input of blood test results, thus delaying the availability of the prediction result. 
With these questions in mind, this study aimed to develop a rapidly applicable model for use 
in all kinds of ACS, based on outcomes in unselected, contemporary patients. An additional 
goal of this study was to evaluate the use of modern data mining / machine learning 
techniques for model development. Most established risk scores have been developed using 
traditional statistical methods such as logistic regression techniques. We hoped that more 
advanced, partially non-linear algorithms, which have only rarely been applied in medical 
science, would prove useful in optimising model accuracy. 
METHODS 
Patient cohorts 
Derivation cohort 
The AMIS (Acute Myocardial Infarction in Switzerland) registry was initiated in 1997 and 
prospectively collects data from ACS patients admitted to 67 Swiss hospitals.[17] While 
initially only patients with myocardial infarction were included, the database was extended in 
2001 to include patients suffering from the complete spectrum of ACS (hence called “AMIS-
Plus”). Collection and analysis of data in the AMIS-Plus registry has been approved by the 
regional ethics committees of all participating hospitals. The derivation cohort for model 
development consisted of patients included in this registry between October 2001 and May 
2005. After exclusion of 185 datasets with missing (or nonsensical) values for age (>120 
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years), systolic blood pressure (<30 or > 300 mm Hg) or heart rate (<15 or > 300/minute) 
7520 sufficiently complete datasets remained. 
AMIS validation cohort 
All patients included in the AMIS-Plus database between June 2005 and July 2006 (n = 2854) 
represented the independent validation dataset for the model. No patients were excluded from 
the AMIS validation dataset. 
External validation cohort 
The Krakow Region (Malopolska State) ACS registry selectively included patients treated 
with a non-invasive strategy in 29 hospitals without on-site PCI facilities in Malopolska State, 
Poland between 2002 and 2006 (n = 2635).[18, 19] No patients were excluded. 
Model development 
The development of the AMIS model followed typical machine learning methodology.[20] 
After establishing the variable to be predicted – in-hospital death – the data were pre-
processed into a format suitable for algorithm consumption. In a second step a variety of 
algorithms were tested regarding their predictive performance. Software packages used for 
data preparation were SPSS Clementine 10.0, and for model development the open source 
software Weka 3.4.7 (available at http://www.cs.waikato.ac.nz/~ml/weka/index.html).  
Of the information collected in the AMIS-Plus registry 86 variables are assessed at admission. 
From these, variable selection was performed using the J48 decision tree learner (a variant of 
C4.5 provided by Weka),[20] combined with a sequential backward deletion process, which 
starts by learning a model with all variables and then repeatedly tests which variable can be 
discarded without decreasing the overall model prediction quality.[21] Since some machine 
learning algorithms are limited to categorical variables, the data were pre-processed either by 
applying categories or by using the fixed-bin discretisation algorithm provided by Weka. We 
used 10-fold cross-validation to establish the predictive power of the model, as assessed using 
the c-statistic (i.e. the area under the curve, range 0-1) of the model’s receiver operating 
characteristic (ROC).[22] 
To determine the best suitable prediction algorithm we compared the performance with 
respect to the c-statistic and computational complexity of 30 data mining algorithms from the 
Weka data mining toolkit using 10-fold cross validation and the variables determined by the 
sequential backward deletion process.  
Comparisons with other ACS risk scores 
Model performance of the AMIS model was compared with the TIMI risk score for STEMI 
and the Simple Risk Index.[7, 9] These two risk prediction scores were chosen for comparison 
with the AMIS model because of their similar applicability at first patient contact, without 
input of blood test results. The GRACE risk model could not be directly compared to the 
AMIS model due to absence of the variables “elevated cardiac enzyme levels at admission” 
and “initial serum creatinine level” in the AMIS-Plus database.[16] The c-statistics achieved 
with the different models were compared according to the non-parametric method described 
by DeLong.[23]  
RESULTS 
Patient characteristics 
The derivation cohort consisted of 7520 entries to the AMIS-Plus registry between October 
2001 and May 2005. The presenting characteristics of these patients are summarized in Table 
1. Hospital mortality for this cohort was 7.5%.  
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Table 1. Admission characteristics of patients from the AMIS-Plus registry used in 
model development and validation 
  Derivation cohort Validation cohort 
  (n = 7520) (n = 2854) 
  Oct 2001-May 2005 June 2005-July 2006 
Age, years 65.9 (13.4) 66.1 (13.4) 
Male, n (%) 5415 (72.0%) 2062 (72.2%) 
Systolic BP, mm Hg 134 (27) 136 (28) 
Heart rate, min-1 79 (20) 79 (21) 
Killip ≥ II 1858 (25.3%) 503 (17.6%) 
Resuscitation before admission 341 (4.5%) 87 (3.0%) 
Previous MI, angina or PCI 2560 (34.0%) 1117 (39.0%) 
History of heart failure 341 (4.5%) 121 (4.2%) 
History of stroke / TIA 422 (5.6%) 168 (5.9%) 
Atrial fibrillation 376 (5.0%) 140 (4.9%) 
Hypertension 4075 (54.2%) 1680 (58.9%) 
Hypercholesterolemia 4169 (55.4%) 1419 (49.7%) 
Current smoker 2836 (37.7%) 947 (33.2%) 
Diabetes mellitus 1506 (20.0%) 542 (19.0%) 
STEMI 4571 (60.8%) 1597 (56.0%) 
Non-STE-ACS 2949 (39.2%) 1257 (44.0%) 
ECG at presentation 
 ST elevation 4300 (57.2%) 1491 (52.2%) 
 Q wave 1228 (16.3%) 283 (9.9%) 
 ST depression 2264 (30.1%) 800 (28.0%) 
 T wave changes 2120 (28.2%) 704 (24.7%) 
 LBBB 372 (5.0%) 129 (4.5%) 
 RBBB 428 (5.7%) 121 (4.2%) 
Values are number (percent) or mean (SD). BP, blood pressure; MI, myocardial infarction; 
PCI, percutaneous coronary intervention; TIA, transient ischemic attack; LBBB, left bundle 
branch block; RBBB, right bundle branch block. 
Model characteristics 
Selection of input variables was performed according to data analysis algorithms as described 
in the Methods section. We found that a critical mass of prognostic information was achieved 
using 7 key variables. The c-statistic did not improve, but rather tended to decrease when 
additional input variables were included in the model (Figure 1). The combination of input 
variables found to provide the best discriminative performance were 1) age, 2) Killip class, 3) 
systolic blood pressure, 4) heart rate, 5) pre-hospital cardio-pulmonary resuscitation, 6) 
history of heart failure, and 7) history of cerebrovascular disease. Notably, all 7 variables are 
available at first patient contact at the bedside. Model output was an estimate of in-hospital 
mortality risk for each patient. The best performing – in terms of accuracy and robustness – of 
the 30 machine learning algorithms tested was the “Averaged One-Dependence Estimators” 
(AODE) algorithm, an extension of the Naïve Bayes algorithm first reported in 2002.[24, 25] 
This provided the basis for the final model, which we named the “AMIS model”. The AODE 
algorithm also has the advantage of delivering a computationally highly efficient model with a 
complexity of the order (2*72) for classification, allowing its implementation on a variety of 
devices including hand-held computers or mobile telephones.  
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Performance of the AMIS model 
Using the AMIS model, the c-statistic for the derivation cohort was 0.875 (95% CI 0.86 – 
0.89). As shown in Figure 2A, the discriminatory capacity of the AMIS model compared 
favourably to the TIMI risk score, which delivered a c-statistic of 0.803 (95% CI 0.79 – 0.82). 
Similarly, the AMIS score clearly outperformed the Simple Risk Index, which thanks to its 
simplicity can be considered to be a pre-hospital, bedside point of care risk prediction tool (c-
statistic 0.813, 95% CI 0.79 – 0.83). The AMIS model performed significantly superior to 
both other scores (p <0.0001 for both comparisons), while the performance of the TIMI risk 
index and the Simple Risk index were similar (p = 0.24). Since differences exist between 
patient characteristics of the AMIS model development cohort (registry of complete ACS 
spectrum) and the other scores (thrombolysis trials), subgroup analysis was performed in 
STEMI vs. non-STE-ACS patients, younger and older patients, and patients treated by 
thrombolysis vs. primary PCI or a primary conservative strategy (Table 2). This demonstrated 
a consistently superior performance of the AMIS model in all subgroups. Interestingly, when 
tested on our derivation cohort, similar performance for patients with and without STEMI 
could also be observed for the TIMI score and the Simple Risk Index, despite the fact that 
these models were developed and validated on STEMI cohorts.  
Calibration of predictions was tested by dividing the cohort into 5 categories based on 
increasing predicted risk, as shown in Figure 2B. Calibration of the model proved to be 
excellent, delivering close matches between mean predicted and effective hospital mortality 
rates for each category.  
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Table 2. Discriminative capacity of different risk prediction models in subgroup analyses 
  Derivation cohort  Validation cohort Krakow cohort 
  N AMIS TIMI SRI  N AMIS TIMI SRI N AMIS TIMI  SRI 
Whole cohort 7520 0.875 0.803 0.813 2854 0.868 0.835 0.817 2635 0.842 0.724 0.784 
STEMI vs. Non-STE-ACS 
 STEMI 4571 0.879 0.816 0.812 1597 0.879 0.827 0.815 818 0.760 0.592 0.746 
 Non-STE-ACS 2949 0.868 0.794 0.821 1257 0.851 0.839 0.831 1817 0.859 0.773 0.815 
Age 
 Age ≥65 years 4013 0.805 0.712 0.731 1589 0.798 0.750 0.751 1766 0.783 0.719 0.758  
 Age <65 years 3507 0.886 0.844 0.829 1265 0.879 0.844 0.814 869 0.802 0.662 0.791 
Primary treatment strategy 
 Primary PCI 4453 0.884 0.783 0.808 2138 0.891 0.802 0.815 N/A N/A N/A N/A 
 Thrombolysis 980 0.853 0.833 0.781 68 0.855 0.873 0.784  
 No revasc. Tx. 2087 0.788 0.673 0.707 648 0.742 0.684 0.695  
Values represent the number of patients in each subgroup and the c-statistic for the corresponding cohort, model and subgroup. AMIS, AMIS 
model; STEMI, ST elevation myocardial infarction; Non-STE-ACS, Non ST elevation acute coronary syndrome; TIMI, TIMI risk score; SRI, 
Simple Risk Index; No revasc. Tx., no primary revascularisation therapy. N/A, not applicable. 
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Validation of the AMIS model 
Prospective validation of the AMIS model was performed on an independent cohort of 2854 
patients subsequently included in the AMIS-Plus registry – with no exclusions – between 
June 2005 and July 2006, with an overall in-hospital mortality rate of 5.5%. The c-statistic of 
the AMIS model for this validation cohort was 0.868 (95% CI 0.84 – 0.90). The performance 
of the AMIS model on the whole cohort (Figure 2C) and in the subgroup analyses (Table 2) 
basically mirrored the results achieved for the derivation cohort, also in comparison to the 
TIMI score (0.835, 95% CI 0.81 – 0.86) and Simple Risk Index (0.817, 95% CI 0.78 – 0.85). 
Again, the AMIS model significantly outperformed both other scores (p = 0.004 compared to 
the TIMI risk score, p = 0.0002 compared to the Simple Risk Index). Importantly, the ROC 
curve of the AMIS model was positioned above the curves of the other models, with no 
crossover points, during their whole course, indicating its superiority over the complete range 
of risks (Figure 2C). We attributed the similar accuracy of the AMIS model in both its 
derivation cohort and independent validation dataset to the fact that 10-fold cross-validation 
had already been used as in internal validation technique while developing the model in the 
derivation dataset. 
Since the AMIS model was developed and validated on a Swiss dataset in which the majority 
of patients were treated by primary PCI, we sought further validation of the model on an 
external cohort treated with a more conservative strategy. The Krakow Region (Malopolska) 
ACS registry selectively included patients treated with a non-invasive strategy in 29 hospitals 
in the greater Krakow area (Poland) between 2002 and 2006.[18, 19] Among the 2635 
patients included in this registry (57% male, mean age 68.2 ± 11.5 years, 31% STEMI) 
hospital mortality was 7.6%. The c-statistic using the AMIS model for this cohort was 0.842 
(95% CI 0.82 – 0.87), compared to 0.724 (95% CI 0.69 – 0.76) for the TIMI risk score and 
0.784 (95% CI 0.75 – 0.82) for the Simple Risk Index (Figure 2E). In this heterogenous 
cohort, the AMIS model was significantly more accurate than both other scores (p <0.0001 
for both comparisons). Risk calibration was maintained with the AMIS model over the 
complete range of risks (Figure 2F). Subgroup analysis for the performance of the three risk 
prediction models in this cohort is listed in Table 2. 
Prediction of late mortality 
Although developed and validated for the prediction of in-hospital mortality, we also tested 
the predictive accuracy of the AMIS model on mortality of ACS patients at 12 months. The 
AMIS-Plus study group began enrolling patients in a registry to assess post-discharge 
mortality in July 2006. Up until August 2008 post-discharge mortality during the first year 
was 3.8%, so that 1-year total mortality – including hospital mortality –came to 8.9% for this 
cohort of 1972 patients with ACS. The c-statistic for the AMIS model in predicting 12 month 
mortality in this cohort was 0.877 (95% CI 0.86 – 0.90). 
Comparison of machine learning algorithms 
A pre-specified goal of this study was to evaluate the use of modern machine learning 
techniques for model development in comparison to more traditional statistical methods such 
as logistic regression. When using the same 7 variables, models based on the AODE 
algorithm (the AMIS model) or logistic regression performed similarly well in the derivation 
cohort (c-statistic 0.875, 95% CI 0.86 – 0.89, and 0.874, 95% CI 0.86 – 0.89, respectively, p = 
ns). However, when these two models, both developed on the same derivation cohort, were 
tested on the more heterogeneous Krakow validation cohort, the AODE-based model proved 
to be much more robust and clearly outperformed the logistic regression-based model (c-
statistic 0.842, 95% CI 0.82 – 0.87, vs. 0.746, 95% CI 0.70 – 0.79, p <0.0001).  
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DISCUSSION 
In this paper we report the development and validation of a novel risk prediction model for 
ACS. The AMIS model had excellent predictive performance both in the derivation cohort 
and in two independent validation cohorts, which differed from each other in important 
aspects. The model performed well both with regard to discriminative precision (c-statistic) 
and risk calibration.  
Since a number of risk prediction scores for patients with myocardial infarction or ACS are 
already established, the specific advantages of the new AMIS model will be recapitulated 
here. First, the AMIS model is applicable to the complete range of ACS. We could show 
similar discriminative capacity for different subgroups, such as patients with STEMI or non-
STE-ACS, for younger and more elderly patients, and for patients managed with different 
treatment strategies (Table 2). Furthermore, the model was developed on patients from a 
contemporary nationwide Swiss registry, which included all subsets of patients not 
traditionally represented in the databases of randomised controlled trials. This is reflected by 
the inclusion of the variables “pre-hospital mechanical resuscitation” and “history of 
cerebrovascular disease” in the model. These variables have not been included in most 
previously reported risk prediction tools.  
Second, all 7 variables required for risk calculation with the AMIS model (Table 2) are 
rapidly available at first patient contact in the pre-hospital phase. Once a brief clinical 
assessment has been made, risk prediction can be calculated without the input of blood test 
results. Since a major goal of a risk prediction model is to optimise early patient management, 
this early availability appears advantageous. The absence of ECG or blood test variables from 
the AMIS model may seem counter-intuitive. However, during model development we found 
that many variables known to be independent predictors of risk did not improve 
discriminative precision with the AODE algorithm. These included STEMI versus non-STE-
ACS, time from symptom onset to revascularisation therapy, the presence of atrial fibrillation 
at admission, or a history of diabetes. 
Third, the AMIS model is very easy to use. The mortality risk is available directly upon 
entering the 7 variables into an appropriate calculator. This could be the online calculator 
publicly available at the AMIS-Plus web site (www.amis-plus.ch), or, for use by ambulance 
personnel or during house visits, the model could be loaded on a handheld computer or even a 
mobile telephone, digital aides which are currently widely available. 
A prespecified goal of this study was to apply advanced data mining / machine learning 
techniques for model derivation, an approach which proved to be most valuable. A main 
strength of the AMIS model lies less in the choice of variables, but rather in the way in which 
variable information is processed by the model – based on the AODE algorithm[24, 25] – to 
calculate predicted risk. This became evident in the manner in which the AODE-based model 
clearly outperformed a conventional logistic regression model in the Krakow validation 
cohort, although both models were derived from the same cohort using the same variables 
(see results section).  
In medical science, logistic regression has been the mainstay of model generation. An 
alternative approach in machine learning is the Naive Bayes algorithm. Numerous approaches 
have been proposed to improve the classification accuracy of Naive Bayes by weakening the 
attribute independence assumption. To maintain the simple structure and low computational 
cost, research has focussed on the one-dependence estimator, an approach chosen by the 
“averaged one-dependence estimator” (AODE) algorithm, initially described by Webb in 
2002. The strength of this dynamic algorithm is the ability to alter the co-efficient of each 
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variable used in the model in dependence of the value of the previous variable in the decision 
tree. Thus, for example, the co-efficient assigned to systolic blood pressure of an individual 
will vary according his age. We are unaware of other prediction tools used in medical science 
applying the AODE algorithm.  
Up until now the only model which estimated risk based on bedside clinical variables alone 
was the Simple Risk Index, using age, systolic blood pressure and heart rate. Although 
modelled and validated for patients with STEMI, it was noteworthy that when tested on our 
cohort – a contemporary, broad ACS population – the Simple Risk Index performed similarly 
in STEMI and non-STE-ACS (Table 2). This is consistent with a previous report on the 
discriminative capacity of the Simple Risk Index (c-statistic 0.73) in a large non-STE-ACS 
database.[26] In our independent and external validation datasets the c-statistics of the Simple 
Risk Index remained inferior to the AMIS model.  
The AMIS model, as any other risk stratification tool, estimates risk for patients treated 
according to current standards, and does not represent the natural course of ACS. It should 
therefore be emphasized that the model should not be used to delay hospital admission or 
withhold treatment from patients estimated to be at low risk of short-term mortality. That 
being said, there is evidence to support the concept that patients with increased baseline risk 
have the largest benefit from early and aggressive therapy.[27] Despite this, data from the 
CRUSADE quality improvement initiative and the GRACE registry clearly showed that high-
risk ACS patients are being treated less aggressively than their low-risk counterparts, and that 
this undertreatment was associated with increased risk-adjusted in-hospital mortality.[28, 29] 
One might hope that more widespread use of simple, point of care risk prediction tools such 
as the AMIS model might improve this “risk-treatment paradox”. 
Limitations 
The Global Registry of Acute Coronary Events (GRACE) score,[16] a robust and well 
validated model which was recently developed on the basis of a large international ACS 
registry, is recommended for risk prediction across the entire spectrum of ACS.[1] The fact 
that we were not able to compare its performance directly with the AMIS model, due to the 
absence of two required variables in our datasets (“elevated cardiac enzyme levels at 
admission” and “initial serum creatinine levels”), is a limitation of this study. In its original 
publication,[16] c-statistics of the GRACE model in its derivation (0.83) and validation 
datasets (0.85 in a subsequent, independent GRACE registry cohort, and 0.79 in the external 
GUSTO IIb cohort) were comparable to those achieved by the AMIS model in its 
corresponding independent validation cohorts, suggesting similar levels of predictive 
accuracy. 
Like the GRACE score, the AMIS model includes the variable “pre-hospital resuscitation”. 
This may appear of questionable value to the everyday clinical use of the model in decision-
making, since these patients, which accounted for 4.5% of the derivation cohort and 3.0% of 
the validation cohort, evidently need to be managed on a ”high risk” basis. Similarly, the 
“high risk” variables “history of heart failure” and “history of stroke” were present in all 
cohorts at a frequency of below 6% (see Table 1). When these 3 variables were omitted from 
the model, the c-statistic declined only moderately from 0.879 to 0.845 with an AODE-based 
model in the derivation cohort (Figure 1A). This underscores the limited value of additional 
variables beyond age and baseline parameters of haemodynamic status (Killip class, systolic 
blood pressure and heart rate) for the prediction of early ACS mortality. However, we felt that 
the added accuracy warranted the inclusion of these 3 easily assessed and clinically important 
variables, especially with regard to use of the model in population-based analyses, such as 
risk-adjusted benchmarking or quality control.  
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Conclusion 
The AMIS model reproducibly provides risk prediction of sufficient quality for daily clinical 
practice for patients suffering from the entire spectrum of acute coronary syndromes at a very 
early stage of patient care, enabling optimisation of management decisions. 
ACKNOWLEDGEMENTS 
We gratefully acknowledge the work of the steering committee and all participating hospitals 
of the AMIS-Plus project (www.amis-plus.ch) and the Krakow Region ACS registry. 
FUNDING  
David J. Kurz receives financial support to from the Swiss Heart Foundation. 
COMPETING INTERESTS 
Conflicts of interest: none declared. 
FIGURE LEGENDS 
Figure 1: Critical mass of prognostic information for model optimisation. 
A, Bar chart depicting discriminative performance (c-statistic) in relation to the number of 
variables included in the model. B, Receiver Operator Characteristic Curves for the AMIS 
model (7 variables), the Simple Risk Index (3 variables) and the Killip Classification when 
used as a single variable in the derivation dataset. 
Figure 2: Performance of the AMIS model in comparison to established risk prediction tools. 
A,C,E, ROC curves and c-statistic of the AMIS model, the TIMI risk score, and the Simple 
Risk Index. B,D,E, Risk calibration of the AMIS model, depicting effective mortality of 
patients discreditized into 5 categories of increasing predicted risk. A and B depict results 
from the derivation dataset, C and D from the independent AMIS-Plus validation dataset, E 
and F from the Krakow Region (Malopolska) ACS registry. 
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